Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma

Our data demonstrate that afatinib is an effective drug for patients with ESCC expressing higher phosphorylation level of EGFR. And for patients with lower p-EGFR in tumors, paclitaxel in combination with afatinib might be a promising therapeutic strategy in ESCC.